1. Home
  2. GPCR vs GRFS Comparison

GPCR vs GRFS Comparison

Compare GPCR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$63.38

Market Cap

6.3B

Sector

N/A

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.71

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPCR
GRFS
Founded
2016
1940
Country
United States
Spain
Employees
N/A
23800
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.5B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GPCR
GRFS
Price
$63.38
$8.71
Analyst Decision
Strong Buy
Hold
Analyst Count
11
2
Target Price
$104.64
$10.15
AVG Volume (30 Days)
778.2K
612.5K
Earning Date
05-29-2026
01-01-0001
Dividend Yield
N/A
1.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.33
Revenue Next Year
N/A
$6.50
P/E Ratio
N/A
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$13.24
$6.19
52 Week High
$94.90
$11.14

Technical Indicators

Market Signals
Indicator
GPCR
GRFS
Relative Strength Index (RSI) 32.83 39.04
Support Level $60.42 $8.66
Resistance Level $72.00 $9.11
Average True Range (ATR) 3.33 0.27
MACD -1.01 -0.08
Stochastic Oscillator 18.38 27.18

Price Performance

Historical Comparison
GPCR
GRFS

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: